IL105456A - Vaccines of attenuated respiratory syncytial virus - Google Patents

Vaccines of attenuated respiratory syncytial virus

Info

Publication number
IL105456A
IL105456A IL10545693A IL10545693A IL105456A IL 105456 A IL105456 A IL 105456A IL 10545693 A IL10545693 A IL 10545693A IL 10545693 A IL10545693 A IL 10545693A IL 105456 A IL105456 A IL 105456A
Authority
IL
Israel
Prior art keywords
virus
rsv
attenuated
respiratory syncytial
cold
Prior art date
Application number
IL10545693A
Other languages
English (en)
Hebrew (he)
Other versions
IL105456A0 (en
Original Assignee
American Home Prod
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod, Us Health filed Critical American Home Prod
Publication of IL105456A0 publication Critical patent/IL105456A0/xx
Publication of IL105456A publication Critical patent/IL105456A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Vertical, Hearth, Or Arc Furnaces (AREA)
IL10545693A 1992-04-21 1993-04-19 Vaccines of attenuated respiratory syncytial virus IL105456A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87274692A 1992-04-21 1992-04-21
US3994593A 1993-04-09 1993-04-09

Publications (2)

Publication Number Publication Date
IL105456A0 IL105456A0 (en) 1993-08-18
IL105456A true IL105456A (en) 1996-12-05

Family

ID=26716607

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10545693A IL105456A (en) 1992-04-21 1993-04-19 Vaccines of attenuated respiratory syncytial virus

Country Status (18)

Country Link
US (3) US5922326A (ko)
EP (1) EP0640128B1 (ko)
JP (1) JP3883202B2 (ko)
KR (1) KR100257171B1 (ko)
AT (1) ATE181359T1 (ko)
AU (1) AU683840B2 (ko)
CA (1) CA2118509C (ko)
DE (1) DE69325370T2 (ko)
DK (1) DK0640128T3 (ko)
ES (1) ES2132233T3 (ko)
GR (1) GR3031208T3 (ko)
HU (1) HU220189B (ko)
IL (1) IL105456A (ko)
MX (1) MX9302278A (ko)
NZ (1) NZ252857A (ko)
RU (1) RU2139729C1 (ko)
UA (1) UA41315C2 (ko)
WO (1) WO1993021310A1 (ko)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
TW275632B (ko) * 1992-04-21 1996-05-11 American Cyanamid Co
DE69409243T2 (de) 1993-08-06 1998-08-06 Connaught Lab Inaktivierte respiratorische synzytial-virus-impfstoffe
US7223410B1 (en) 1994-08-05 2007-05-29 Sanofi Pasteur Limited Inactivated respiratory syncytial viral vaccines
WO1996010400A1 (en) * 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
US6083925A (en) 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US20050287540A1 (en) * 1995-09-27 2005-12-29 Murphy Brian R Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
JPH11512609A (ja) 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
AU2438597A (en) * 1996-04-04 1997-10-29 Regents Of The University Of Michigan, The Attenuated respiratory syncytial virus
US6077514A (en) * 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
ATE234631T1 (de) * 1996-07-12 2003-04-15 Aventis Pasteur Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
EP2112220A3 (en) * 1996-07-15 2010-01-06 The Government of the United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
AU4427897A (en) * 1996-09-27 1998-04-17 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
FR2764903A1 (fr) * 1997-06-23 1998-12-24 Pasteur Institut Detection des infections par des paramyxovirus (virus respiratoire syncitial et virus parainfluenza) utilisant des polynucleotides codant de la proteine l
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US7662397B2 (en) 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6482414B1 (en) 1998-08-13 2002-11-19 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6579528B1 (en) 1998-08-13 2003-06-17 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
WO2000061611A2 (en) 1999-04-13 2000-10-19 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7820182B2 (en) * 1999-07-09 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
EP1287152B1 (en) 1999-07-09 2008-12-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Human-bovine chimeric respiratory syncytial virus vaccines
CA2403979A1 (en) 2000-04-03 2001-10-11 The University Of Pittsburgh Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
KR20040071678A (ko) * 2001-09-28 2004-08-12 유니버시티 오브 사우스 플로리다 Ｒｓｖ 유전자 발현 백신
WO2003091401A2 (en) 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1572108A4 (en) * 2002-09-27 2008-09-17 Medimmune Vaccines Inc FUNCTIONAL MUTATIONS OF RSV (RESPIRATORY SYNCYTIAL VIRUS)
CA2518924C (en) * 2003-03-18 2016-06-07 Wyeth Holdings Corporation Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv
ATE469170T1 (de) * 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
ES2345492T3 (es) 2003-12-23 2010-09-24 Medimmune, Llc Sistema multiplasmido para la produccion del virus de la gripe.
WO2005116260A2 (en) * 2004-05-25 2005-12-08 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
EP2049662A4 (en) * 2006-07-21 2009-12-30 Medimmune Llc METHODS AND COMPOSITIONS FOR INCREASING REPLICATION CAPACITY OF A FLU VIRUS
CA2659267C (en) * 2006-08-09 2016-12-13 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
JP5666905B2 (ja) * 2007-06-18 2015-02-12 メディミューン，エルエルシー ヘマグルチニンポリペプチド中に変化を有するインフルエンザｂウイルス
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
SG192501A1 (en) 2008-07-11 2013-08-30 Medimmune Llc Influenza hemagglutinin and neuraminidase variants
WO2010093537A2 (en) * 2009-02-12 2010-08-19 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
GB201003630D0 (en) 2010-03-04 2010-04-21 Novartis Ag Avian rotavirus
SG11201401137TA (en) 2011-10-07 2014-07-30 Medimmune Llc Influenza hemagglutinin variants
EP3875112A1 (en) 2012-04-13 2021-09-08 The United States of America, as Represented By the Secretary, Department of Health and Human Services Genetically stable live attenuated respiratory syncytial virus vaccine and its production
CN105189756B (zh) 2013-03-14 2021-06-11 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
CA2902560A1 (en) * 2013-03-14 2014-09-25 President And Fellows Of Harvard College Nanoparticle-based compositions
US11235050B2 (en) 2015-10-29 2022-02-01 Emory University Chimeric RSV, immunogenic compositions, and methods of use
RU2746280C1 (ru) * 2020-08-03 2021-04-12 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) Штамм респираторно-синцитиального вируса RSV/Novosibirsk/66Hl/2018 для использования в диагностике респираторно-синцитиальной вирусной инфекции и исследования эффективности противовирусных препаратов in vitro

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
US5250298A (en) * 1988-10-07 1993-10-05 University Of Delaware Live attenuated newcastle disease virus vaccines and preparation thereof

Also Published As

Publication number Publication date
JPH07505891A (ja) 1995-06-29
UA41315C2 (uk) 2001-09-17
KR100257171B1 (ko) 2000-05-15
EP0640128B1 (en) 1999-06-16
RU2139729C1 (ru) 1999-10-20
CA2118509A1 (en) 1993-10-28
AU4290793A (en) 1993-11-18
US5882651A (en) 1999-03-16
MX9302278A (es) 1994-07-29
HUT69992A (en) 1995-09-28
KR950701382A (ko) 1995-03-23
US5922326A (en) 1999-07-13
EP0640128A1 (en) 1995-03-01
DE69325370T2 (de) 1999-10-14
DK0640128T3 (da) 1999-11-22
WO1993021310A1 (en) 1993-10-28
IL105456A0 (en) 1993-08-18
ATE181359T1 (de) 1999-07-15
DE69325370D1 (de) 1999-07-22
NZ252857A (en) 1997-06-24
GR3031208T3 (en) 1999-12-31
HU220189B (hu) 2001-11-28
US6284254B1 (en) 2001-09-04
HU9403023D0 (en) 1994-12-28
RU94045898A (ru) 1996-09-20
ES2132233T3 (es) 1999-08-16
JP3883202B2 (ja) 2007-02-21
AU683840B2 (en) 1997-11-27
CA2118509C (en) 2009-05-19

Similar Documents

Publication Publication Date Title
EP0640128B1 (en) Attenuated respiratory syncytial virus vaccine compositions
Stott et al. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus
Crowe Jr et al. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees
Karron et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children
Byrd et al. Animal models of respiratory syncytial virus infection
Crowe Jr et al. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV
CN100354425C (zh) 减毒的人－牛嵌合呼吸道合胞病毒疫苗的生产
US3992522A (en) Temperature-sensitive recombinant mutant viruses and a process for producing same
US7150984B2 (en) Attenuated human rotavirus vaccine
US7169395B1 (en) Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
EP0567100B1 (en) Respiratory syncytial virus (RSV) mutant and pharmaceutical composition containing such a mutant
Prince et al. Respiratory syncytial virus infection in owl monkeys: viral shedding, immunological response, and associated illness caused by wild-type virus and two temperature-sensitive mutants
Chanock et al. Live viral vaccines for respiratory and enteric tract diseases
Piazza et al. Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection
US7932074B1 (en) Multivalent human-bovine rotavirus vaccine
US7223410B1 (en) Inactivated respiratory syncytial viral vaccines
Hsu et al. Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus
US7083795B1 (en) Inactivated respiratory syncytial viral vaccines
Crowe Jr et al. The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo
US20180318411A1 (en) Method of vaccination with an attenuated rsv vaccine formulation
Norrby Toward new viral vaccines for man
Faverio et al. Immunoprophylaxis of group B respiratory syncytial virus infection in cotton rats
PL172087B1 (pl) Szczepionka zawierajaca atenuowany wirus oddechowy (RS) PL PL PL
Dolezalová et al. Ability of temperature-sensitive mutants of the recombinant influenza S/N (H2N1) virus to induce immunity to parental (H0N1 and H2N2) viruses
STAREK et al. Ability of Temperature-Sensitive Mutants of the Recombinant Influenza SIN (H2N1) Virus to Induce Immunity to Parental (HON1 and H2N2) Viruses

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
HCA Change of name of proprietor(s) after amalgamation
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees